Business Context and Reporting Period
Company: Solesence, Inc. (formerly Nanophase Technologies Corporation)
Reporting Period: Quarter ended March 31, 2025
Business Overview: Solesence is a science-driven company focused on beauty and life-science markets, specifically skin health and medical diagnostics. The company recently rebranded and uplisted its stock to the NASDAQ Capital Market under the symbol SLSN on April 8, 2025. Its strategy prioritizes consumer products and active pharmaceutical ingredients (APIs) over legacy advanced materials.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $14,625,000 | $9,868,000 |
| Gross Profit | $3,382,000 | $3,580,000 |
| Gross Margin | 23.1% | 36.3% |
| Net Income | $80,000 | $893,000 |
| Net Income Per Share (Diluted) | $0.00 | $0.02 |
| Cash and Cash Equivalents | $1,817,000 | $2,018,000 |
| Net Cash Used in Operating Activities | ($7,221,000) | ($3,855,000) |
| Total Debt (Related Party) | $12,492,000 | $5,000,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 48% year-over-year, driven primarily by a 59% increase in Consumer Products revenue ($12.9M vs $8.1M). Personal Care Ingredients and Advanced Materials remained relatively flat.
- Margin Compression: Despite revenue growth, Gross Profit decreased by 5.5% to $3.4M. Gross margin contracted from 36.3% to 23.1% due to manufacturing inefficiencies, increased volume costs, and facility improvements.
- Profitability Decline: Net income dropped 91% to $80,000. This was caused by a 35% increase in Selling, General, and Administrative (SG&A) expenses (driven by higher credit loss allowances and legal costs) and a 12% increase in R&D expenses.
- Balance Sheet Shifts: Accounts receivable nearly doubled to $9.1M (net), and inventory increased to $21.9M. Total debt obligations surged to $12.5M, primarily due to increased utilization of related-party lines of credit for accounts receivable and inventory.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management is prioritizing the expansion of consumer products and skin health ingredients, viewing legacy advanced materials as a diminishing portion of the business.
- Capital Requirements: The company expects capital expenditures for 2025 to range between $2 million and $4 million, funded by operations, existing credit lines, and potential new debt.
- Liquidity Risk: The company relies heavily on related-party financing (Beachcorp, LLC and Strandler, LLC), with maturities set for October 1, 2025. Failure to refinance or extend these facilities poses an operating risk.
- Customer Concentration: The top three customers accounted for 42% of revenue in Q1 2025 (down from 61% in Q1 2024). A significant risk involves an exclusive supply agreement with BASF Corporation; failure to meet performance requirements could trigger a mandatory sale of production equipment to the customer.
- Operational Challenges: Management cited manufacturing inefficiencies and the inability to fully pass through raw material cost increases as key drivers of margin compression. Tariffs on international materials are also being monitored.
Investor Verification Checklist
- Debt Maturity: Verify the status of refinancing for the $12.5M in related-party debt maturing in October 2025.
- BASF Agreement: Review the specific performance metrics in the BASF supply agreement to assess the risk of equipment sale and revenue loss.
- Cash Burn: Monitor the trend of negative operating cash flow ($7.2M used in Q1) against the current cash balance of $1.8M.
- Margin Recovery: Assess whether the company can achieve the projected cost efficiencies and scale to improve gross margins from the current 23.1%.
- Customer Concentration: Track the revenue contribution of the top three customers to ensure diversification efforts are effective.